Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of apoptotic DNA fragmentation. [GOC:hjd, GOC:TermGenie, PMID:15572351]
Positive regulation of apoptotic DNA fragmentation is a crucial step in programmed cell death, ensuring the controlled dismantling of the cell to prevent harmful inflammation and maintain tissue homeostasis. It involves a series of precisely regulated events that lead to the fragmentation of the cell's DNA into specific, ladder-like fragments, a hallmark of apoptosis.
This process is initiated by various signals, including death receptor activation, mitochondrial stress, and DNA damage. These signals trigger the activation of caspases, a family of proteases that play a central role in apoptotic execution.
One critical caspase, caspase-3, acts as a central executioner, directly cleaving and activating downstream targets, including DNA fragmentation factor 40 (DFF40, also known as caspase-activated DNase or CAD).
DFF40 exists in an inactive complex with DFF45. Upon activation, caspase-3 cleaves DFF45, releasing DFF40, which then translocates to the nucleus and initiates DNA fragmentation.
DFF40 is a nuclease, an enzyme that specifically cleaves DNA at internucleosomal linker regions, resulting in the characteristic ladder-like pattern of DNA fragmentation observed during apoptosis. This fragmentation ensures that DNA is broken down into smaller fragments, which can then be easily degraded and recycled by the cell.
In addition to DFF40, other nucleases and endonucleases can also contribute to DNA fragmentation.
Positive regulation of apoptotic DNA fragmentation ensures the orderly and efficient breakdown of the cell's genetic material, preventing uncontrolled release and potential damage to surrounding cells. This process is essential for maintaining tissue integrity and preventing disease development.'
"
Protein | Definition | Taxonomy |
---|---|---|
Apoptosis regulator BAX | An apoptosis regulator BAX that is encoded in the genome of human. [PRO:SY, UniProtKB:Q07812] | Homo sapiens (human) |
Heat shock factor protein 1 | A heat shock factor protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q00613] | Homo sapiens (human) |
Interleukin-6 | An interleukin-6 that is encoded in the genome of human. [PRO:JAN, UniProtKB:P05231] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
vorinostat | vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
zm 336372 | N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source | benzamides | |
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
celastrol | monocarboxylic acid; pentacyclic triterpenoid | anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite | |
quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
abt-737 | aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound | anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor | |
chir-265 | aromatic ether | ||
az-628 | AZ-628: a multikinase inhibitor; structure in first source | benzamides | |
GDC-0879 | indanes; ketoxime; primary alcohol; pyrazoles; pyridines | antineoplastic agent; B-Raf inhibitor | |
plx4032 | aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide | antineoplastic agent; B-Raf inhibitor | |
dabrafenib | 1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide | anticoronaviral agent; antineoplastic agent; B-Raf inhibitor | |
bi 653048 bs h3po4 | BI 653048 BS H3PO4: structure in first source | ||
tak-632 | TAK-632 : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by (cyclopropanecarbonyl)amino, 4-fluoro-3-{2-[3-(trifluoromethyl)phenyl]acetamido}phenoxy, and cyano groups at positions 2, 6 and 7, respectively. It is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAF(V600E), BRAF(WT), respectively. | (trifluoromethyl)benzenes; aromatic ether; benzothiazoles; cyclopropylcarboxamide; monofluorobenzenes; nitrile; secondary carboxamide | antineoplastic agent; apoptosis inducer; B-Raf inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; necroptosis inhibitor |
dinaciclib | pyrazolopyrimidine | ||
n2-(1h-indazole-5-yl)-n6-methyl-3-nitropyridine-2,6-diamine | KRIBB11 : A member of the class of indazoles that is 1H-indazole substituted by a [6-(methylamino)-3-nitropyridin-2-yl]amino group at position 5. It is an inhibitor of heat shock factor 1 (IC50 = 1.2muM) and suppresses tumour growth in mouse xenograft models. N2-(1H-indazole-5-yl)-N6-methyl-3-nitropyridine-2,6-diamine: a heat shock factor 1 antagonist; structure in first source |